ARDEA BIOSCIENCES, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1994-01-01

Employees: 107

Market Cap: -

Website: http://www.ardeabio.com

Clinical Trials

NSAID Drug Interaction Study

Phase 1

Completed

Conditions: Gout

Interventions: Drug: lesinurad 400 mg
Drug: naproxen 250 mg
Drug: indomethacin 25 mg

First Posted Date: 2013-06-24

Last Posted Date: 2013-11-08

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 24

Registration Number: NCT01884272

RDEA3170 and Febuxostat Drug Interaction Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: RDEA3170 10 mg
Drug: Febuxostat 40 mg
Drug: placebo

First Posted Date: 2013-06-21

Last Posted Date: 2014-01-09

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 21

Registration Number: NCT01883167

Single and Multiple Dose Study in Japanese Subjects

Phase 1

Completed

Conditions: Gout

Interventions: Drug: RDEA3170 and Placebo

First Posted Date: 2013-06-07

Last Posted Date: 2014-01-09

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 46

Registration Number: NCT01872832

Lesinurad and Febuxostat Combination Extension Study in Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: lesinurad
Drug: febuxostat

First Posted Date: 2013-03-11

Last Posted Date: 2018-01-30

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 196

Registration Number: NCT01808144

Lesinurad and Allopurinol Combination Extension Study in Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Lesinurad

First Posted Date: 2013-03-11

Last Posted Date: 2017-01-24

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 717

Registration Number: NCT01808131

Single and Multiple Dose Study in Japanese

Phase 1

Completed

Conditions: Gout

Interventions: Drug: Lesinurad
Drug: Placebo

First Posted Date: 2012-12-06

Last Posted Date: 2013-06-19

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 40

Registration Number: NCT01744379

Open-Label Lesinurad Monotherapy Extension Study in Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: lesinurad

First Posted Date: 2012-07-26

Last Posted Date: 2016-05-26

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 143

Registration Number: NCT01650246

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Phase 3

Completed

Conditions: Tophaceous Gout

Interventions: Drug: Placebo
Drug: Lesinurad
Drug: Febuxostat

First Posted Date: 2012-01-16

Last Posted Date: 2016-05-26

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 330

Registration Number: NCT01510769

Combining Lesinurad With Allopurinol in Inadequate Responders

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Placebo
Drug: Lesinurad
Drug: Allopurinol

First Posted Date: 2012-01-13

Last Posted Date: 2016-08-18

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 607

Registration Number: NCT01510158

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Phase 3

Completed

Conditions: Gout

Interventions: Drug: lesinurad
Drug: Placebo

First Posted Date: 2012-01-12

Last Posted Date: 2016-02-12

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 214

Registration Number: NCT01508702

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy